Organon & Co (OGN)
Net profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 864,000 | 1,023,000 | 917,000 | 1,351,000 | 2,160,000 |
| Revenue | US$ in thousands | 6,403,000 | 6,263,000 | 6,174,000 | 6,304,000 | 8,096,000 |
| Net profit margin | 13.49% | 16.33% | 14.85% | 21.43% | 26.68% |
December 31, 2024 calculation
Net profit margin = Net income ÷ Revenue
= $864,000K ÷ $6,403,000K
= 13.49%
Organon & Co's net profit margin has displayed a declining trend over the years, with figures of 26.68% in 2020, 21.43% in 2021, 14.85% in 2022, 16.33% in 2023, and 13.49% in 2024. This indicates that the company's profitability relative to its total revenue has been decreasing gradually. It is essential for Organon & Co to closely monitor and address the factors contributing to this trend to ensure sustainable financial health and optimize profitability in the future.
Peer comparison
Dec 31, 2024
Company name
Symbol
Net profit margin
Organon & Co
OGN
13.49%
Abbott Laboratories
ABT
31.95%
AbbVie Inc
ABBV
7.59%
ACADIA Pharmaceuticals Inc
ACAD
23.64%
Alkermes Plc
ALKS
23.58%
Amphastar P
AMPH
21.79%
ANI Pharmaceuticals Inc
ANIP
-3.01%
Arcus Biosciences Inc
RCUS
-109.69%
Biomarin Pharmaceutical Inc
BMRN
15.00%
Bristol-Myers Squibb Company
BMY
-18.53%
Catalyst Pharmaceuticals Inc
CPRX
33.33%